ETFS Holding Biogen Idec Inc

 
ETF Quotes for ETFS Holding Biogen Idec Inc top ^
  • Holdings: Biogen Idec Inc , Celgene Corp , Gilead Sciences Inc , Amgen Inc , Regeneron Pharmaceuticals Inc ,
  • Morningstar Rating: 5 Stars
Sign-up for ibb investment picks
  • Holdings: Biogen Idec Inc , TripAdvisor Inc , Alexion Pharmaceuticals Inc , Delta Air Lines Inc , Avago Technologies Ltd ,
  • Morningstar Rating: 4 Stars
Sign-up for sphb investment picks
  • Holdings: Djus Short Sml Size T , Djus Long Sml Size T , NPS Pharmaceuticals Inc , Akorn Inc , Biogen Idec Inc ,
  • Morningstar Rating: 2 Stars
Sign-up for siz investment picks
  • Holdings: Gilead Sciences Inc , Amgen Inc , Celgene Corp , Biogen Idec Inc , Biomarin Pharmaceutical Inc ,
  • Morningstar Rating: 5 Stars
Sign-up for bbh investment picks
  • Holdings: Biogen Idec Inc , CVS Health Corp , Bristol-Myers Squibb Company , Home Depot Inc , Gilead Sciences Inc ,
  • Morningstar Rating: 4 Stars
Sign-up for pwb investment picks
  • Holdings: Biogen Idec Inc , Biomarin Pharmaceutical Inc , Gilead Sciences Inc , Illumina Inc , Regeneron Pharmaceuticals Inc ,
  • Morningstar Rating: 3 Stars
Sign-up for pbe investment picks

 
Stock Quotes for Biogen Idec Inc top ^
  • Industry: Biotechnology
  • Sector: Healthcare
  • Stock Style: Large Growth
  • Stock Type: Aggressive Growth
  • Morningstar Rating: 3 Stars
Sign-up for biib investment picks

 
News Articles for Biogen Idec Inc top ^
Biogen Idec (NASDAQ: BIIB) today announced that two leading neuroscientists have joined the company to advance its research in neurodegenerative diseases.
Sign-up for Leading Researchers Join Biogen Idec to Advance Drug Discovery for Neurodegenerative Diseases investment picks
Biogen Idec (NASDAQ: BIIB) and Swedish Orphan Biovitrum AB (publ) (Sobi) (STO: SOBI) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) of ELOCTA ™ (rFVIIIFc), a recombinant factor VIII Fc fusion protein product candidate for the treatment of hemophilia A.
Sign-up for Biogen Idec and Sobi Announce European Medicines Agency Validates ELOCTA™ (rFVIIIFc) Marketing Authorization Application for Review investment picks
Biogen Idec Inc. (NASDAQ: BIIB) announced today that it will present at the 2014 Deutsche Bank BioFEST Conference.
Sign-up for Biogen Idec to Present at the 2014 Deutsche Bank BioFEST Conference investment picks
COPENHAGEN, Denmark, Nov.
Sign-up for Forward Pharma Sues Biogen Idec Over Tecfidera(R) Sales in Germany investment picks
Biogen Idec (NASDAQ: BIIB) will present data supporting its approved hemophilia therapies at the 56 th Annual Meeting of the American Society of Hematology (ASH) taking place in San Francisco, December 6-9.
Sign-up for Biogen Idec to Present Data from Hematology Programs, Including ELOCTATE™ and ALPROLIX® at ASH Annual Meeting investment picks
Biogen Idec Inc. (NASDAQ:BIIB) today announced it will report fourth quarter and year-end 2014 financial results on Wednesday, January 28, 2015, before the financial markets open.
Sign-up for Biogen Idec to Report Fourth Quarter and Year End 2014 Financial Results on January 28, 2015 investment picks
Biogen Idec Inc. (NASDAQ: BIIB) announced today that it will present at the 33 rd Annual J.P. Morgan Healthcare Conference.
Sign-up for Biogen Idec to Present at the 33rd Annual J.P. Morgan Healthcare Conference investment picks
Biogen Idec (NASDAQ: BIIB) and Columbia University Medical Center have formed a $30 million strategic alliance to conduct genetics discovery research on the underlying causes of disease and to identify new treatment approaches.
Sign-up for Biogen Idec and Columbia University Medical Center to Conduct Collaborative Genetics Research investment picks
Biogen Idec (NASDAQ: BIIB) today announced top-line results from the Phase 2 acute optic neuritis (AON) RENEW trial in which treatment with anti-LINGO-1 showed evidence of biological repair of the visual system.
Sign-up for Biogen Idec Reports Positive Top-Line Results from Phase 2 Anti-LINGO-1 Trial in People with Acute Optic Neuritis investment picks

Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
ETFS Holding Biogen Idec Inc
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: ETFS Holding Bill Barrett Corporation  |  Next: ETFS Holding Biomarin Pharmaceutical, Inc.